Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Invested Capital (2018 - 2025)

Arcturus Therapeutics Holdings' Invested Capital history spans 8 years, with the latest figure at $214.0 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 11.2% year-over-year to $214.0 million; the TTM value through Dec 2025 reached $214.0 million, down 11.2%, while the annual FY2025 figure was $214.0 million, 11.2% down from the prior year.
  • Invested Capital reached $214.0 million in Q4 2025 per ARCT's latest filing, down from $224.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $355.7 million in Q1 2021 to a low of $173.4 million in Q3 2022.
  • Average Invested Capital over 5 years is $261.3 million, with a median of $262.9 million recorded in 2024.
  • Peak YoY movement for Invested Capital: soared 1994.76% in 2021, then crashed 41.25% in 2022.
  • A 5-year view of Invested Capital shows it stood at $276.1 million in 2021, then grew by 16.15% to $320.7 million in 2022, then decreased by 13.16% to $278.5 million in 2023, then decreased by 13.48% to $241.0 million in 2024, then decreased by 11.2% to $214.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Invested Capital are $214.0 million (Q4 2025), $224.6 million (Q3 2025), and $231.1 million (Q2 2025).